GenMont Biotech Inc (3164) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of GenMont Biotech Inc TWD 11.88, price TWD 16.30, upside -27.1%, quality 69 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch GenMont Biotech Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 15.60 TWD – 28.12 TWD · fair‑value band 8.48 TWD – 15.26 TWD · the 16.30 TWD price screens above the 11.88 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow GenMont Biotech in your weekly email
Every Wednesday you see whether GenMont Biotech is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
GenMont Biotech Incorporation engages in the research and development, manufacture, and sale of various probiotic health products in Taiwan, Singapore, Mainland Chinese, and internationally. The company offers OEM and ODM services, including functional probiotic raw materials, capsules, powder, tablets, and liquid products.
Show more
GenMont Biotech Incorporation engages in the research and development, manufacture, and sale of various probiotic health products in Taiwan, Singapore, Mainland Chinese, and internationally. The company offers OEM and ODM services, including functional probiotic raw materials, capsules, powder, tablets, and liquid products. GenMont Biotech Incorporation was founded in 2000 and is based in Tainan City, Taiwan.
Stock analysis
GenMont Biotech Inc (3164) currently trades at 16.30 TWD, while our model-based Fair Value estimate is 11.88 TWD, implying the stock looks roughly 37.2% overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 13.49 TWD per share, and 3 of the 25 models we run sit above the 16.30 TWD price.
Bear case: the Earnings-Based group reads lowest at 5.83 TWD, and 22 of the 25 models stay below the price. Evidence for this calculation is low.
Scenario range: 8.48 TWD (bear) to 15.26 TWD (bull), the price of 16.30 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 69/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
GenMont Biotech Inc reported revenue of 401M TWD in FY2025 versus 428M TWD in FY2021, a compound −1.6%/yr. Reported net income was 57.2M TWD in FY2025, compounding −15.7%/yr from FY2021.
Key figures
Market cap 1.4B TWD (≈ $43.9M) · P/E ratio 24.7 · P/S ratio 3.52 · EPS (TTM) 0.6600 TWD · Dividend yield 4.9% · Net margin 14.3% · Return on equity 2.5% · Return on assets (EBIT) 3.6%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 47 out of 100 (low confidence).
What moves the price
The share trades about 16% below its 52-week high and 4% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −27%, 3164 screens richer than that median.
Fair Value models
Bear 8.48 TWDFair Value 11.88 TWDBull 15.26 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.72/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+4.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.3%
Start year 2020 (pandemic). Over 10 years: −2.8% a year
Revenue growth 22 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.9%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+7.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year+2.6%
Dividend (yield on the price)4.9%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.24% → 14%
⚠ Revenue per share shrinking 3.0%/yr over ~10Y (margin trend unclear) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−1.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about −3.2% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 650 stocks
Beats the industry median on 12/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score69 · Top 25%
Fair Value upside−27% · Above median
Profitability
Return on equity (TTM)3% · Above median
Return on assets1% · Above median
Net margin (TTM)11% · Above median
Operating margin (TTM)−8% · Bottom 25%
Growth and dividend
Revenue growth−10% · Below median
Dividend yield (TTM)4.9% · Top 25%
Balance sheet
Debt / equity0.03× · Below median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/E (TTM)24.7× · Cheaper than median
P/B1.05× · Cheaper than median
P/S (TTM)3.58× · Cheaper than median
P/FCF0.6× · Cheapest 25%
EV/EBITDA12.9× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)10· sector 0
HEALTH (low debt)98· sector 97
DIVIDEND (yield)98· sector 23
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is GenMont Biotech Inc (3164) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 11.88 TWD versus a price of 16.30 TWD, about −27% upside (overvalued).
What is the fair value of 3164?
Our model-based fair value for GenMont Biotech Inc is 11.88 TWD (as of Sep 24, 2026), built from audited fundamentals. The current price: 16.30 TWD.
What is the quality score of 3164?
GenMont Biotech Inc has a Quality Score of 69/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for GenMont Biotech Inc (3164)?
Our model-based price target is the fair value of 11.88 TWD (as of Sep 24, 2026) from 25 valuation models. Cautious scenario 8.48 TWD, optimistic scenario 15.26 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the GenMont Biotech Inc stock forecast for 2026?
Our models put fair value at 11.88 TWD, about −27% upside versus a price of 16.30 TWD (overvalued). Cautious scenario 8.48 TWD, optimistic scenario 15.26 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of GenMont Biotech Inc (3164)?
GenMont Biotech Inc reported trailing-twelve-month revenue of about 391M TWD (latest available figure, as of Sep 24, 2026).
Does GenMont Biotech Inc pay a dividend?
GenMont Biotech Inc currently shows a dividend yield of about 4.91% relative to its recent price (as of Sep 24, 2026).
What growth is priced into GenMont Biotech Inc (3164)?
For today's price to be fair in a discounted-cash-flow model, GenMont Biotech Inc would have to grow free cash flow by -1.7 % per year for five years (discount rate 9.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +4.3 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 3164 use?
Our models discount GenMont Biotech Inc at 9.0 %: a base by market capitalisation (nano), damped by beta 0.08, country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For GenMont Biotech Inc that is -1.7 % per year a year over ten years, using the same discount rate (9.0 %) and the same formula as our fair value.
How much growth has GenMont Biotech Inc (3164) delivered so far?
Over the past 5 years revenue at GenMont Biotech Inc grew +4.3 % a year. The price currently implies -1.7 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of GenMont Biotech Inc (3164) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into GenMont Biotech Inc (-1.7 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of GenMont Biotech Inc (3164)?
The free-cash-flow yield on the price is 5.90 %: that much free cash flow GenMont Biotech Inc produces per unit of market value. When it exceeds the discount rate of our models (9.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of GenMont Biotech Inc (3164)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For GenMont Biotech Inc it is 11.88 TWD per share (as of Sep 24, 2026), against a price of 16.30 TWD. It is the blended result of 25 valuation models (cash flow, earnings, asset, dividend).
Is GenMont Biotech Inc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 3164 trades above its calculated fair value: price 16.30 TWD, fair value 11.88 TWD, a gap of about −27% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 3164?
No. The price is what the market pays today (16.30 TWD); the fair value is what the company's own numbers justify (11.88 TWD). For GenMont Biotech Inc the two are 4.42 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is GenMont Biotech Inc worth?
The market values GenMont Biotech Inc at about 1.4B TWD (market capitalisation, as of Sep 24, 2026). Per share that is 16.30 TWD; our models calculate a fair value of 11.88 TWD per share.
What do the bullish and bearish scenarios say about 3164?
Our models span a range for GenMont Biotech Inc: cautious scenario 8.48 TWD, base 11.88 TWD, optimistic 15.26 TWD per share (as of Sep 24, 2026, price 16.30 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 3164?
GenMont Biotech Inc trades at a price-to-earnings ratio of 24.7 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 11.88 TWD is built from several models across several years. Other multiples: P/B 1.1, P/S 3.6, EV/EBITDA 12.9.
How solid is the balance sheet of GenMont Biotech Inc (3164)?
Balance-sheet figures for GenMont Biotech Inc (as of Sep 24, 2026): return on equity 2.5%, debt of 0.03 per unit of equity. They feed the Quality Score of 69/100, which measures business quality independently of the share price.
How far is 3164 from its 52-week high?
GenMont Biotech Inc trades at 16.30 TWD, about 16% below its 52-week high of 19.30 TWD and 4% above the low of 15.60 TWD (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 11.88 TWD is for.
Which stocks are comparable to GenMont Biotech Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is GenMont Biotech Inc stock attractive at the current price?
The data as of Sep 24, 2026: price 16.30 TWD, calculated fair value 11.88 TWD (−27%), Quality Score 69/100, from 25 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 3164 calculated?
We run GenMont Biotech Inc through 25 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 11.88 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.2 % above its aggregate fair value. GenMont Biotech Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of GenMont Biotech Inc (3164)?
The closing price on Sep 24, 2026 was 16.30 TWD. Our model-based fair value is 11.88 TWD, about −27% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with GenMont Biotech Inc right now?
The price sits above even our optimistic bull case (15.26 TWD). The favourable scenario is already priced in. Solid but not exceptional quality (69/100) and above fair value, neither a clear bargain nor a standout compounder. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of GenMont Biotech Inc
How large is the market capitalisation of GenMont Biotech Inc (3164)?
The market capitalisation of GenMont Biotech Inc is 1.4B TWD (≈ $43.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of GenMont Biotech Inc (3164)?
The price-to-sales ratio of GenMont Biotech Inc is 3.52 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of GenMont Biotech Inc (3164)?
Earnings per share at GenMont Biotech Inc are 0.6600 TWD (price ÷ EPS = P/E 24.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of GenMont Biotech Inc (3164)?
The dividend yield of GenMont Biotech Inc is 4.9% (payout 121%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of GenMont Biotech Inc (3164)?
The net margin of GenMont Biotech Inc is 14.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of GenMont Biotech Inc (3164)?
The return on equity (ROE) of GenMont Biotech Inc is 2.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of GenMont Biotech Inc (3164)?
On an EBIT basis the return on assets of GenMont Biotech Inc is 3.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of GenMont Biotech Inc (3164)?
The operating margin of GenMont Biotech Inc is −8.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at GenMont Biotech Inc (3164)?
Revenue at GenMont Biotech Inc is growing −10.3% versus a year earlier (3y avg +2.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at GenMont Biotech Inc (3164)?
Earnings per share at GenMont Biotech Inc are growing −74.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does GenMont Biotech Inc (3164) carry?
The net debt of GenMont Biotech Inc is 6.6M TWD (fiscal year 2025, ≈ 0.1 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch GenMont Biotech Inc in the live analysis
One click puts GenMont Biotech Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
